Rantus Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 30-06-2024
- Paid Up Capital ₹ 2.70 Cr
as on 30-06-2024
- Company Age 21 Year, 9 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 39.46 Cr
as on 30-06-2024
- Revenue %
(FY 2019)
- Profit 67.53%
(FY 2019)
- Ebitda 82.92%
(FY 2019)
- Net Worth -6.44%
(FY 2019)
- Total Assets -2.39%
(FY 2019)
About Rantus Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.70 Cr.
The company has closed loans amounting to ₹39.46 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Umamaheswara Kotte, Soudhamini Narravula, and Ratna Kotti serve as directors at the Company.
- CIN/LLPIN
U24239TG2003PTC040459
- Company No.
040459
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Feb 2003
- Date of AGM
26 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Rantus Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umamaheswara Kotte  | Managing Director | 07-Feb-2003 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Soudhamini Narravula | Director | 07-Feb-2003 | Current |
| Ratna Kotti | Director | 17-Feb-2003 | Current |
Financial Performance and Corporate Structure Insights of Rantus Pharma.
Rantus Pharma Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 67.53% increase in profit. The company's net worth dipped by a decrease of 6.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rantus Pharma?
In 2019, Rantus Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rantuss Drugs Private Limited
Active 12 years 4 monthsUmamaheswara Kotte and Ratna Kotti are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 18 Aug 2009 | ₹11.36 Cr | Satisfied |
State Bank Of India Creation Date: 15 Nov 2008 | ₹9.40 Cr | Satisfied |
State Bank Of India Creation Date: 08 Oct 2008 | ₹8.70 Cr | Satisfied |
How Many Employees Work at Rantus Pharma?
Rantus Pharma has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rantus Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rantus Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
